Docoh
Loading...

MACK Merrimack Pharmaceuticals

Filed: 21 Feb 20, 4:30pm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 19, 2020

 

 

Merrimack Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware 001-35409 04-3210530

(State or Other Jurisdiction

of Incorporation)

 (Commission
File Number)
 (IRS Employer
Identification No.)

One Broadway, 14th Floor

Cambridge, MA

 02142
(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (617)441-1000

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule14a-12 under the Exchange Act (17 CFR240.14a-12)

 

Pre-commencement communications pursuant to Rule14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))

 

Pre-commencement communications pursuant to Rule13e-4(c) under the Exchange Act (17 CFR240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common stock, $0.01 par value MACK Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule12b-2 of the Securities Exchange Act of 1934(§240.12b-2 of this chapter).

Emerging growth company   ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Item 5.08. Shareholder Director Nominations.

The Board of Directors (the “Board”) of Merrimack Pharmaceuticals, Inc. (the “Company”) has set May 28, 2020 as the date for the Company’s 2020 Annual Meeting of Stockholders (the “Annual Meeting”).

Proposals of stockholders intended to be presented at the Annual Meeting pursuant to Rule14a-8 promulgated under the Securities Exchange Act of 1934, as amended, must be received by the Company at its principal executive offices, One Broadway, 14th Floor, Cambridge, Massachusetts 02142, no later than March 10, 2020 in order to be included in the proxy statement and proxy card relating to that meeting.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MERRIMACK PHARMACEUTICALS, INC.
Date: February 21, 2020  By:  

/s/ Gary Crocker

    

Gary Crocker

President